<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01248741</url>
  </required_header>
  <id_info>
    <org_study_id>H10-01987</org_study_id>
    <nct_id>NCT01248741</nct_id>
  </id_info>
  <brief_title>CT-validation of Ultrasound Based Planning for High Dose Rate (HDR) Prostate Brachytherapy Using Vitesse</brief_title>
  <acronym>Vitesse</acronym>
  <official_title>High Dose Rate (HDR)Prostate Brachytherapy With Vitesse tm</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>British Columbia Cancer Agency</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>British Columbia Cancer Agency</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      High Dose Rate (HDR) temporary prostate brachytherapy offers a precise form of dose&#xD;
      escalation for prostate cancer. Needles are placed, the position is confirmed and treatment&#xD;
      is delivered. Previously High Dose Rate prostate brachytherapy was performed under&#xD;
      TransRectal UltraSound (TRUS) guidance but planned with Computed Tomography (CT) imaging&#xD;
      which introduced a source of error through needle displacement while transporting and&#xD;
      repositioning patient. Recently Varian has introduced a one-step procedure where both implant&#xD;
      and planning are based on UltraSound imaging and performed without patient repositioning.&#xD;
      This planning system is approved by Health Canada and is commercially available.&#xD;
&#xD;
      This study will use High Dose Rate brachytherapy to treat 20 men. Treatment will be planned&#xD;
      with TransRectal UltraSound and validated using Computed Tomography imaging.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Twenty men with intermediate risk prostate cancer, suitable for the combination of external&#xD;
      beam radiotherapy and High Dose Rate brachytherapy will be entered in this study. High Dose&#xD;
      Rate brachytherapy will be performed using TransRectal UltraSound guidance and then planned&#xD;
      using both cone-beam Computed Tomography and TransRectal UltraSound. Planning by Computed&#xD;
      Tomography is to check the reliability and reproducibility of UltraSound imaging to correctly&#xD;
      identify the needle positions. Correct needle localization is essential because this is the&#xD;
      basis for determining source dwell positions, dose calculation and dose optimization.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Accuracy of Needle Tip Identification on TransRectal UltraSound Compared to Computed Tomography</measure>
    <time_frame>Treatment was planned and delivered based on ultrasound identification of needles and needle tips relative to prostate. All measurements and comparisons of measurements pertain to the day of the procedure.</time_frame>
    <description>Precise location of the tip of each needle in 3-dimensional space relative to the prostate determines the pattern of dose delivery. Inaccuracies in needle tip location may lead to differences detected between UltraSound(US)-based and Computed Tomography (CT)-based plans.The distance of the needle tip (as identified on either CT images or US images) protruding beyond the template was measured in mm. The template acted as a fixed reference point as it was locked into the stabilizer/stepper apparatus. The 2 protrusion readings for each needle tip were compared, the difference recorded in mm, and categorized as &lt; 1 mm, 1-2 mm, 2-3 mm and &gt; 3 mm.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Prostate Cancer</condition>
  <condition>Interstitial Radiation</condition>
  <condition>High Dose Rate Brachytherapy</condition>
  <condition>Ultrasound-based Planning Compared to CT-based Planning</condition>
  <arm_group>
    <arm_group_label>HDR prostate brachytherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>An array of 17 gauge steel needles, 20 cm in length, is inserted under Ultrasound (US) guidance into the prostate and advanced to the base of the prostate. A template is used to maintain spacing and parallelism and the needles are individually locked into the template once positioned. A continuously acquired set of US images is obtained for treatment planning purposes. Each needle is connected to a Varisource afterloader and treatment is delivered using a 10 Curie Iridium-192 source. The needles are then removed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>HDR prostate brachytherapy</intervention_name>
    <description>HDR prostate brachytherapy to be delivered in 2 fractions of 10 Gray as a &quot;boost&quot; combined with external beam radiotherapy</description>
    <arm_group_label>HDR prostate brachytherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients must have histologically proven adenocarcinoma of the prostate.&#xD;
&#xD;
          2. Patients must have intermediate risk prostate cancer. (Clinical stage ≤ T2c, Gleason&#xD;
             score = 7 and initial prostate specific antigen (iPSA) ≤ 20, or Gleason score ≤ 6 and&#xD;
             iPSA &gt; 10 and ≤ 20.&#xD;
&#xD;
          3. Patients must be fit for general or spinal anaesthetic.&#xD;
&#xD;
          4. Patients must have an estimated life expectancy of at least 10 years.&#xD;
&#xD;
          5. Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of&#xD;
             0 - 2.&#xD;
&#xD;
          6. Patients must have no contraindications to interstitial prostate brachytherapy.&#xD;
&#xD;
          7. Patients on coumadin therapy must be able to stop therapy safely for at least 7 days.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Men not able to fully understand the trial and the informed consent document&#xD;
&#xD;
          -  Men suffering from claustrophobia and unable to have a Computed Tomography scan&#xD;
&#xD;
          -  Men not wishing to have a cone-beam Computed Tomography scan following the insertion&#xD;
             of the High Dose Rate brachytherapy needles to verify the accuracy of the treatment&#xD;
             plan&#xD;
&#xD;
          -  Men who cannot safely discontinue blood thinners for a few days.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthew Schmid, MSc</last_name>
    <role>Study Director</role>
    <affiliation>British Columbia Cancer Agency Dept of Radiation Physics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>BCCA Center for the Southern Interior</name>
      <address>
        <city>Kelowna</city>
        <state>British Columbia</state>
        <zip>V1Y 5L3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 3, 2010</study_first_submitted>
  <study_first_submitted_qc>November 24, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2010</study_first_posted>
  <results_first_submitted>September 23, 2020</results_first_submitted>
  <results_first_submitted_qc>November 17, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 11, 2020</results_first_posted>
  <last_update_submitted>November 17, 2020</last_update_submitted>
  <last_update_submitted_qc>November 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>British Columbia Cancer Agency</investigator_affiliation>
    <investigator_full_name>Juanita Crook</investigator_full_name>
    <investigator_title>MD FRCPC</investigator_title>
  </responsible_party>
  <keyword>prostate cancer</keyword>
  <keyword>interstitial radiation,</keyword>
  <keyword>brachytherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>20 patients were recruited from the target population of men with localized prostate cancer undergoing radical radiotherapy consisting of a combination of external beam radiation and 2 fractions of 10 Gray each of High Dose Rate brachytherapy</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>HDR Prostate Brachytherapy</title>
          <description>HDR prostate brachytherapy: HDR prostate brachytherapy to be delivered in 2 fractions of 10 Gray as a &quot;boost&quot; combined with external beam radiotherapy</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Localized Prostate Cancer</title>
          <description>Patients had either intermediate risk or favorable high risk disease suitable for definitive radiotherapy.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65" lower_limit="50" upper_limit="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Accuracy of Needle Tip Identification on TransRectal UltraSound Compared to Computed Tomography</title>
        <description>Precise location of the tip of each needle in 3-dimensional space relative to the prostate determines the pattern of dose delivery. Inaccuracies in needle tip location may lead to differences detected between UltraSound(US)-based and Computed Tomography (CT)-based plans.The distance of the needle tip (as identified on either CT images or US images) protruding beyond the template was measured in mm. The template acted as a fixed reference point as it was locked into the stabilizer/stepper apparatus. The 2 protrusion readings for each needle tip were compared, the difference recorded in mm, and categorized as &lt; 1 mm, 1-2 mm, 2-3 mm and &gt; 3 mm.</description>
        <time_frame>Treatment was planned and delivered based on ultrasound identification of needles and needle tips relative to prostate. All measurements and comparisons of measurements pertain to the day of the procedure.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Localized Prostate Cancer</title>
            <description>Patients had either intermediate risk or favorable high risk disease suitable for definitive radiotherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Accuracy of Needle Tip Identification on TransRectal UltraSound Compared to Computed Tomography</title>
          <description>Precise location of the tip of each needle in 3-dimensional space relative to the prostate determines the pattern of dose delivery. Inaccuracies in needle tip location may lead to differences detected between UltraSound(US)-based and Computed Tomography (CT)-based plans.The distance of the needle tip (as identified on either CT images or US images) protruding beyond the template was measured in mm. The template acted as a fixed reference point as it was locked into the stabilizer/stepper apparatus. The 2 protrusion readings for each needle tip were compared, the difference recorded in mm, and categorized as &lt; 1 mm, 1-2 mm, 2-3 mm and &gt; 3 mm.</description>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Localized Prostate Cancer</title>
          <description>Patients had either intermediate risk or favorable high risk disease suitable for definitive radiotherapy.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>colostomy</sub_title>
                <description>sigmoid stricture</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>urethral stricture</sub_title>
                <description>urethral stricture requiring dilatation</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Juanita Crook</name_or_title>
      <organization>British Columbia Cancer Agency</organization>
      <phone>2507123958</phone>
      <email>jcrook@bccancer.bc.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

